Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial shows reduction risk of heart failure hospitalizations.
1. Treatment with IV ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency and acute heart failure with a left ventricular ejection fraction less than 50%. 2. IV ferric carboxymaltose was generally safe but had no significant effect on the risk of cardiovascular death compared to placebo. Evidence Rating Level: 1